US5554367A
(en)
*
|
1984-10-31 |
1996-09-10 |
Alcon Laboratories, Inc. |
Compositions for treatment of glaucoma
|
US5093126A
(en)
*
|
1987-09-26 |
1992-03-03 |
Alcon Laboratories, Inc. |
Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer
|
US5188826A
(en)
*
|
1988-02-08 |
1993-02-23 |
Insite Vision Incorporated |
Topical ophthalmic suspensions
|
US5192535A
(en)
*
|
1988-02-08 |
1993-03-09 |
Insite Vision Incorporated |
Ophthalmic suspensions
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5660851A
(en)
*
|
1989-12-26 |
1997-08-26 |
Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem |
Ocular inserts
|
US5496471A
(en)
*
|
1990-01-08 |
1996-03-05 |
Ciba-Geigy Corporation |
Apparatus for removing components from solutions
|
US5124154A
(en)
*
|
1990-06-12 |
1992-06-23 |
Insite Vision Incorporated |
Aminosteroids for ophthalmic use
|
US5833665A
(en)
*
|
1990-06-14 |
1998-11-10 |
Integra Lifesciences I, Ltd. |
Polyurethane-biopolymer composite
|
US5252318A
(en)
*
|
1990-06-15 |
1993-10-12 |
Allergan, Inc. |
Reversible gelation compositions and methods of use
|
US5275820A
(en)
*
|
1990-12-27 |
1994-01-04 |
Allergan, Inc. |
Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
|
US5212162A
(en)
*
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
JP2536806B2
(en)
*
|
1991-03-27 |
1996-09-25 |
アルコン ラボラトリーズ インコーポレイテッド |
Topical ophthalmic composition combining gelled polysaccharide and finely divided drug carrier
|
US5182102A
(en)
*
|
1991-07-12 |
1993-01-26 |
Alcon Laboratories, Inc. |
Anti-glaucoma compositions
|
US5320839A
(en)
*
|
1991-10-11 |
1994-06-14 |
Alcon Laboratories, Inc. |
Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use
|
EP0606393A1
(en)
*
|
1991-10-11 |
1994-07-20 |
Alcon Laboratories, Inc. |
Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use
|
JP2873530B2
(en)
*
|
1991-12-13 |
1999-03-24 |
参天製薬株式会社 |
Carboxyvinyl polymer-containing ophthalmic base showing Newtonian viscosity
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
ATE169499T1
(en)
*
|
1992-02-21 |
1998-08-15 |
Alcon Lab Inc |
TOPICAL ANTIGLAUCOMA COMPOSITIONS CONTAINING CARBON HYDRASE INHIBITORS AND BETA BLOCKERS
|
US5296228A
(en)
*
|
1992-03-13 |
1994-03-22 |
Allergan, Inc. |
Compositions for controlled delivery of pharmaceutical compounds
|
TW205503B
(en)
*
|
1992-04-24 |
1993-05-11 |
Ciba Geigy Ag |
Apparatus for removing components from solutions
|
WO1993023082A1
(en)
*
|
1992-05-13 |
1993-11-25 |
Alcon Laboratories, Inc. |
Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
|
AU666957B2
(en)
|
1992-08-28 |
1996-02-29 |
Alcon Laboratories, Inc. |
Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
|
US5520920A
(en)
*
|
1992-08-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
|
DE69311361T2
(en)
*
|
1992-10-13 |
1998-01-08 |
Alcon Lab Inc |
COMPOSITIONS FOR TREATING GLAUCOMA CONTAINING PROSTAGLANDINES AND CLONIDINE DERIVATIVES
|
US5340572A
(en)
*
|
1993-02-08 |
1994-08-23 |
Insite Vision Incorporated |
Alkaline ophthalmic suspensions
|
EP0664699A1
(en)
*
|
1993-08-13 |
1995-08-02 |
Vitaphore Corporation |
Hydrogel-based microsphere drug delivery systems
|
AU684950B2
(en)
*
|
1994-05-06 |
1998-01-08 |
Alcon Laboratories, Inc. |
Use of vitamin E tocopheryl derivatives in ophthalmic compositions
|
US5662919A
(en)
*
|
1994-11-21 |
1997-09-02 |
Alcon Laboratories, Inc. |
Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds
|
US5612027A
(en)
*
|
1995-04-18 |
1997-03-18 |
Galin; Miles A. |
Controlled release of miotic and mydriatic drugs in the anterior chamber
|
US5972326A
(en)
*
|
1995-04-18 |
1999-10-26 |
Galin; Miles A. |
Controlled release of pharmaceuticals in the anterior chamber of the eye
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
WO1997018812A1
(en)
*
|
1995-11-17 |
1997-05-29 |
Alcon Laboratories, Inc. |
Combination therapy for treating glaucoma
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
AU720326B2
(en)
|
1995-12-21 |
2000-05-25 |
Alcon Laboratories, Inc. |
Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
|
US6159458A
(en)
*
|
1997-11-04 |
2000-12-12 |
Insite Vision |
Sustained release ophthalmic compositions containing water soluble medicaments
|
JP2003517441A
(en)
*
|
1998-09-25 |
2003-05-27 |
アルコン ラボラトリーズ, インコーポレイテッド |
Sustained-release and comfortable composition for eye disease and method for treating eye disease
|
EP1124582B1
(en)
|
1998-10-27 |
2003-12-10 |
Alcon Laboratories, Inc. |
Preservative system for topically administrable pharmaceutical compositions
|
WO2000024375A1
(en)
|
1998-10-27 |
2000-05-04 |
Alcon Laboratories, Inc. |
Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
|
US6146622A
(en)
*
|
1998-10-27 |
2000-11-14 |
Alcon Laboratories, Inc. |
Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
|
US6444710B1
(en)
|
1998-10-27 |
2002-09-03 |
Alcon Manufacturing, Ltd. |
Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
|
US6258350B1
(en)
|
1999-01-20 |
2001-07-10 |
Alcon Manufacturing, Ltd. |
Sustained release ophthalmic formulation
|
NZ513164A
(en)
*
|
1999-01-25 |
2006-03-31 |
Nat Jewish Med & Res Center |
Substituted porphyrins
|
US20030032634A1
(en)
*
|
2001-06-01 |
2003-02-13 |
Piganelli Jon D. |
Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
|
WO2000069411A1
(en)
*
|
1999-05-12 |
2000-11-23 |
Alcon Laboratories, Inc. |
Use of polymeric adsorbents in pharmaceutical dosage forms
|
US6730691B1
(en)
|
2000-02-10 |
2004-05-04 |
Miles A. Galin |
Uses of alpha adrenergic blocking agents
|
DE10115282B4
(en)
*
|
2000-03-29 |
2006-03-02 |
Hitachi, Ltd. |
Inlet air control device and internal combustion engine in which it is mounted
|
AR031135A1
(en)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
TOPIC ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF OCULAR INFECTIONS
|
US20040121947A1
(en)
*
|
2000-12-28 |
2004-06-24 |
Oklahoma Medical Research Foundation |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
US20020176842A1
(en)
*
|
2001-04-09 |
2002-11-28 |
Lyn Hughes |
Extended release of active ingredients
|
US6743439B1
(en)
|
2001-06-27 |
2004-06-01 |
Alcon, Inc. |
Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
|
US20040067992A1
(en)
*
|
2001-08-10 |
2004-04-08 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
|
US20030220376A1
(en)
*
|
2001-08-10 |
2003-11-27 |
Pharmacia Corporation |
Methods for treating carbonic anhydrase mediated disorders
|
US20030100594A1
(en)
*
|
2001-08-10 |
2003-05-29 |
Pharmacia Corporation |
Carbonic anhydrase inhibitor
|
WO2003020242A1
(en)
*
|
2001-08-29 |
2003-03-13 |
Srl Technologies, Inc. |
Sustained release preparations
|
CA2464736A1
(en)
*
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
US7001615B1
(en)
|
2001-12-07 |
2006-02-21 |
Alcon, Inc. |
Sustained release ophthalmic, otic and nasal suspension
|
US20060094643A1
(en)
*
|
2002-07-03 |
2006-05-04 |
Yuri Svirkin |
Compositions of hyaluronic acid and methods of use
|
US20050147584A1
(en)
*
|
2004-01-05 |
2005-07-07 |
Allergan, Inc. |
Compositions and methods comprising memantine and polyanionic polymers
|
US20050031652A1
(en)
*
|
2003-02-25 |
2005-02-10 |
Allergan, Inc. |
Compositions and methods comprising memantine and polyanionic polymers
|
US20050277698A1
(en)
*
|
2004-01-05 |
2005-12-15 |
Hughes Patrick M |
Memantine delivery to the back of the eye
|
US20050265955A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Mallinckrodt Inc. |
Sustained release preparations
|
EP1799660A2
(en)
*
|
2004-09-17 |
2007-06-27 |
Comentis, Inc. |
Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
|
EP1797052A1
(en)
*
|
2004-09-17 |
2007-06-20 |
Comentis, Inc. |
Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
|
US20060111388A1
(en)
*
|
2004-11-19 |
2006-05-25 |
University Of North Texas Health Science Center At Fort Worth |
Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
|
JP2008520744A
(en)
*
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
Anti-inflammatory pyrazolopyrimidine
|
JP2008535863A
(en)
*
|
2005-04-08 |
2008-09-04 |
コメンティス,インコーポレーテッド |
Compounds that inhibit β-secretase activity and methods of use thereof
|
US20070077302A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Azaam Alli |
Methods for stabilizing ophthalmic compositions
|
CA2630668C
(en)
*
|
2005-11-22 |
2016-07-12 |
Mcgill University |
Intraocular pressure-regulated early genes and uses thereof
|
WO2008005457A2
(en)
|
2006-06-30 |
2008-01-10 |
Sunesis Pharmaceuticals |
Pyridinonyl pdk1 inhibitors
|
US8158667B2
(en)
*
|
2006-08-21 |
2012-04-17 |
Kador Peter F |
Topical treatment of cataracts in dogs
|
JP5576659B2
(en)
*
|
2006-12-05 |
2014-08-20 |
ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング/ マギル ユニバーシティ |
Methods of using TRK receptor modulators
|
AU2011253937B2
(en)
*
|
2006-12-05 |
2012-09-27 |
The Royal Institution For The Advancement Of Learning/ Mcgill University |
Methods of use of TRK receptor modulators
|
US8968786B2
(en)
|
2007-06-22 |
2015-03-03 |
Board Of Regents, The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
CA2697166A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Comentis, Inc. |
Isophthalamide derivatives inhibiting betasecretase activity
|
KR20100059919A
(en)
*
|
2007-09-24 |
2010-06-04 |
코멘티스, 인코포레이티드 |
(3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
|
ES2464728T3
(en)
|
2008-05-23 |
2014-06-03 |
National Jewish Health |
Compounds for use in the treatment of lesions associated with exposure to an alkylating chemical species
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
US8618096B2
(en)
*
|
2008-07-21 |
2013-12-31 |
The Regents Of The University Of California |
Prodrug compositions and methods for using the same in treating cancer and malaria
|
CN104230901A
(en)
|
2008-09-15 |
2014-12-24 |
加利福尼亚大学董事会 |
Methods and compositions for modulating ire1, src, and abl activity
|
MX2011008647A
(en)
*
|
2009-02-20 |
2011-10-28 |
Micro Labs Ltd |
Storage stable prostaglandin product.
|
EP2467142B1
(en)
|
2009-08-17 |
2016-09-21 |
Memorial Sloan-Kettering Cancer Center |
2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders
|
US9029359B2
(en)
|
2009-09-04 |
2015-05-12 |
Biogen Idec Ma, Inc. |
Heteroaryl Btk inhibitors
|
NZ598985A
(en)
|
2009-09-04 |
2013-07-26 |
Biogen Idec Inc |
Bruton's tyrosine kinase inhibitors
|
WO2011044157A1
(en)
|
2009-10-06 |
2011-04-14 |
Biogen Idec Ma Inc. |
Heterocyclic compounds useful as pdk1 inhibitors
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
AU2010315561B2
(en)
|
2009-10-26 |
2016-10-20 |
Sephoris Pharmaceuticals, Llc |
Treatment of sunburn using analgesics and antihistamines
|
US20130035325A1
(en)
|
2009-11-16 |
2013-02-07 |
The Regents Of The University Of California |
Kinase inhibitors
|
RS54158B1
(en)
|
2009-12-10 |
2015-12-31 |
The Regents Of The University Of California |
Amyloid binding agents
|
SG10201502484SA
(en)
|
2010-03-30 |
2015-05-28 |
Verseon Corp |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
WO2012058645A1
(en)
|
2010-10-29 |
2012-05-03 |
Biogen Idec Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
WO2012112451A1
(en)
|
2011-02-14 |
2012-08-23 |
Allergan, Inc. |
Ester derivatives of bimatoprost compositions and methods
|
PL2710005T3
(en)
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
DK2710007T3
(en)
|
2011-05-17 |
2020-01-27 |
Principia Biopharma Inc |
kinase inhibitors
|
JP2014521594A
(en)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
Long duration dual hormone conjugate
|
WO2013006569A2
(en)
|
2011-07-01 |
2013-01-10 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
JP6342805B2
(en)
|
2011-09-02 |
2018-06-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Substituted pyrazolo [3,4-D] pyrimidine and uses thereof
|
CA2853729A1
(en)
|
2011-10-28 |
2013-05-02 |
Board Of Regents, The University Of Texas System |
Novel compositions and methods for treating cancer
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
AR091273A1
(en)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
PYRIMIDINYL TIROSINE KINASE INHIBITORS
|
EP2858500A4
(en)
|
2012-06-08 |
2016-04-06 |
Biogen Ma Inc |
Inhibitors of bruton's tyrosine kinase
|
WO2013188452A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
CA2882743C
(en)
|
2012-08-27 |
2021-11-30 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
ES2731833T3
(en)
|
2012-09-10 |
2019-11-19 |
Principia Biopharma Inc |
Pyrazolopyrimidine compounds as kinase inhibitors
|
BR112015006828A8
(en)
|
2012-09-26 |
2019-09-17 |
Univ California |
compound, or a pharmaceutically acceptable salt thereof; pharmaceutical composition; use of the compound; and method for modulating the activity of an ire1 protein
|
WO2014066435A1
(en)
|
2012-10-22 |
2014-05-01 |
City Of Hope |
Etp derivatives
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
EP2953950B1
(en)
|
2013-02-11 |
2021-01-13 |
The Regents of The University of California |
Compositions and methods for treating neurodegenerative diseases
|
US9295665B2
(en)
|
2013-03-12 |
2016-03-29 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
EP2968270A4
(en)
|
2013-03-14 |
2016-08-17 |
Univ California |
Modulation of k2p channels
|
EP2968215B1
(en)
|
2013-03-14 |
2021-05-05 |
The Regents of the University of California |
Thiosaccharide mucolytic agents
|
AU2014236370C1
(en)
|
2013-03-14 |
2019-01-17 |
City Of Hope |
5-bromo-indirubins
|
AU2014233520B2
(en)
|
2013-03-15 |
2019-02-21 |
The Regents Of The University Of California |
Modulators of the eIF2alpha pathway
|
MX2015012867A
(en)
|
2013-03-15 |
2016-06-10 |
Verseon Corp |
Multisubstituted aromatic compounds as serine protease inhibitors.
|
AU2014238478B2
(en)
|
2013-03-15 |
2018-07-19 |
Verseon Corporation |
Halogenopyrazoles as inhibitors of thrombin
|
WO2014143643A1
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California, A California Corporation |
Acyclic nucleoside phosphonate diesters
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
CN105338985A
(en)
|
2013-03-15 |
2016-02-17 |
阿勒根公司 |
Bimatoprost for enhancement of leptin production
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2014190207A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
CA2917527C
(en)
|
2013-07-15 |
2022-06-14 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
LT3035926T
(en)
|
2013-08-19 |
2020-11-25 |
The Regents Of The University Of California |
Compounds and methods for treating an epileptic disorder
|
JP2016530273A
(en)
|
2013-08-20 |
2016-09-29 |
シティ・オブ・ホープCity of Hope |
HDAC8 inhibitor for treating cancer
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
TWI659021B
(en)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Inhibitors of kras g12c
|
EP3444251B1
(en)
|
2013-12-11 |
2023-06-07 |
Biogen MA Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
MX370103B
(en)
|
2013-12-11 |
2019-12-02 |
Biogen Ma Inc |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology.
|
TWI673279B
(en)
|
2013-12-23 |
2019-10-01 |
美國紀念斯隆-凱特琳癌症中心 |
Methods and reagents for radiolabeling
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
HRP20220759T1
(en)
|
2014-02-11 |
2022-09-02 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
CA2937752C
(en)
|
2014-02-14 |
2023-02-07 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
CN106029643A
(en)
|
2014-02-20 |
2016-10-12 |
阿勒根公司 |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
SG11201606858RA
(en)
|
2014-02-21 |
2016-09-29 |
Principia Biopharma Inc |
Salts and solid form of a btk inhibitor
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
EP3128842B1
(en)
|
2014-03-26 |
2023-07-26 |
City of Hope |
Treatment of brca1-defective cancer or resistant cancers
|
WO2015157313A1
(en)
|
2014-04-07 |
2015-10-15 |
The Regents Of The University Of California |
Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
|
CA2948621A1
(en)
|
2014-05-13 |
2015-11-19 |
Memorial Sloan Kettering Cancer Center |
Hsp70 modulators and methods for making and using the same
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
US10414814B2
(en)
|
2014-07-03 |
2019-09-17 |
City Of Hope |
Tumor-selective CTLA-4 antagonists
|
EP3954362A1
(en)
|
2014-07-28 |
2022-02-16 |
Sun Pharma Advanced Research Company Ltd |
Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
|
US11072681B2
(en)
|
2014-07-28 |
2021-07-27 |
The Regents Of The University Of California |
Compositions and methods of making polymerizing nucleic acids
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
CN113620978A
(en)
|
2014-09-11 |
2021-11-09 |
加利福尼亚大学董事会 |
mTORC1 inhibitors
|
KR102589658B1
(en)
|
2014-09-15 |
2023-10-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Nucleotide analogs
|
CA2960790A1
(en)
|
2014-09-17 |
2016-03-24 |
Verseon Corporation |
Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
|
JO3556B1
(en)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
Combination therapies for treatment of cancer
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
AU2015327817B2
(en)
|
2014-10-02 |
2020-04-23 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
EP3233056B1
(en)
|
2014-12-15 |
2023-11-15 |
The Johns Hopkins University |
Sunitinib formulations and methods for use thereof in treatment of ocular disorders
|
MA41197B1
(en)
|
2014-12-18 |
2021-01-29 |
Principia Biopharma Inc |
Treatment of pemphigus
|
EP3244907B1
(en)
|
2015-01-13 |
2020-02-19 |
City of Hope |
Ctla4-binding protein peptide-linker masks
|
MX2017009272A
(en)
|
2015-01-16 |
2018-04-11 |
|
Cell penetrating antibodies.
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138138A1
(en)
|
2015-02-25 |
2016-09-01 |
The Regents Of The University Of California |
5ht agonists for treating disorders
|
US11072592B2
(en)
|
2015-02-27 |
2021-07-27 |
The Regents Of The University Of California |
Small molecules that enable cartilage rejuvenation
|
CN107405333A
(en)
|
2015-02-27 |
2017-11-28 |
维颂公司 |
Substituted pyrazole compound as serpin
|
JP2018510138A
(en)
|
2015-02-27 |
2018-04-12 |
カーテナ ファーマシューティカルズ,インク. |
Inhibition of OLIG2 activity
|
WO2016161018A1
(en)
|
2015-03-30 |
2016-10-06 |
City Of Hope |
Mechanically interlocking complexes
|
TW201702232A
(en)
|
2015-04-10 |
2017-01-16 |
亞瑞克西斯製藥公司 |
Substituted quinazoline compounds and methods of use thereof
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
EP3283482B1
(en)
|
2015-04-17 |
2022-04-06 |
Ludwig Institute for Cancer Research Ltd |
Plk4 inhibitors
|
WO2016172726A1
(en)
|
2015-04-24 |
2016-10-27 |
The Regents Of The University Of California |
Modulators of ror1-ror2 binding
|
AU2016265845B2
(en)
|
2015-05-15 |
2020-10-08 |
City Of Hope |
Chimeric antigen receptor compositions
|
US10940206B2
(en)
*
|
2015-05-21 |
2021-03-09 |
Ophtalmis Monaco |
Ophthalmic composition comprising lipoic acid and a mucomimetic polymer
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
WO2016201169A1
(en)
|
2015-06-10 |
2016-12-15 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
MA42510A
(en)
|
2015-06-10 |
2018-06-06 |
Biogen Ma Inc |
FORMS AND COMPOSITIONS OF BIARYL INHIBITORS OF BRUTON TYROSINE KINASE
|
US20180305350A1
(en)
|
2015-06-24 |
2018-10-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
CN114224907A
(en)
|
2015-07-02 |
2022-03-25 |
希望之城 |
Compounds and compositions comprising phosphorothioated oligodeoxynucleotides and methods of use thereof
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
JP7104462B2
(en)
|
2015-08-06 |
2022-07-21 |
シティ・オブ・ホープ |
Cell-permeable protein-antibody conjugate and usage
|
WO2017040693A1
(en)
|
2015-08-31 |
2017-03-09 |
The Regents Of The University Of California |
Broad spectrum antiviral compounds and uses thereof
|
EP3350181B1
(en)
|
2015-09-02 |
2023-11-01 |
The Regents of The University of California |
Her3 ligands and uses thereof
|
EP3350167A4
(en)
|
2015-09-04 |
2019-04-03 |
City of Hope |
Androgen receptor antagonists
|
US11253521B2
(en)
|
2015-09-25 |
2022-02-22 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10801026B2
(en)
|
2015-10-15 |
2020-10-13 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
CA3002924A1
(en)
|
2015-10-23 |
2017-04-27 |
Erx Pharmaceuticals Inc. |
Analogs of celastrol
|
AU2016342352B2
(en)
|
2015-10-23 |
2022-06-02 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclic PDK1 inhibitors for use to treat cancer
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
EA038755B1
(en)
|
2015-11-12 |
2021-10-14 |
Грейбаг Вижн, Инк. |
Aggregating microparticles for providing sustained release of a therapeuic agent for intraocular delivery
|
JP7015059B2
(en)
|
2015-11-16 |
2022-02-15 |
アラクセス ファーマ エルエルシー |
2-substituted quinazoline compounds containing substituted heterocyclic groups and their usage
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
CN108603037B
(en)
|
2015-12-10 |
2020-11-17 |
希望之城 |
Cell penetrating cyanine conjugated antibodies
|
PT3394040T
(en)
|
2015-12-24 |
2022-03-24 |
Univ California |
Cftr regulators and methods of use thereof
|
RU2730855C2
(en)
|
2015-12-24 |
2020-08-26 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа |
Cftr regulators and methods of using
|
AU2017205389B2
(en)
|
2016-01-05 |
2021-05-20 |
The Regents Of The University Of California |
Benzothiazole amphiphiles
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
US11208411B2
(en)
|
2016-03-17 |
2021-12-28 |
The Regents Of The University Of California |
Compositions and methods for treating parasitic diseases
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
US20170312273A1
(en)
|
2016-04-25 |
2017-11-02 |
Forma Therapeutics, Inc. |
Methods of using fasn inhibitors
|
AU2017257151A1
(en)
|
2016-04-29 |
2018-11-15 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
TWI763668B
(en)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
Modulators of the integrated stress pathway
|
TW201808914A
(en)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
Modulators of the integrated stress pathway
|
CN109153688A
(en)
|
2016-05-12 |
2019-01-04 |
安纳考尔医药公司 |
Oxa- boron Polymorphs alkyl ester class and application thereof
|
WO2017205611A1
(en)
|
2016-05-26 |
2017-11-30 |
The Regents Of The University Of California |
Estrogen receptor modulator combinations
|
IL263815B
(en)
|
2016-06-29 |
2022-07-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
|
US11045493B2
(en)
|
2016-07-11 |
2021-06-29 |
The Regents Of The University Of California |
Synthetic melanin nanoparticles and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
CA3031443A1
(en)
|
2016-07-21 |
2018-01-25 |
Biogen Ma Inc. |
Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors
|
US10179787B2
(en)
|
2016-07-29 |
2019-01-15 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
US11780895B2
(en)
|
2016-09-13 |
2023-10-10 |
The Jackson Laboratory |
Targeted DNA demethylation and methylation
|
JP7088912B2
(en)
|
2016-09-15 |
2022-06-21 |
シティ・オブ・ホープ |
Dithio ETP derivative
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
CN110312711A
(en)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
Heterocyclic compound and its application method as RAS inhibitor
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
BR112019012263A2
(en)
|
2016-12-15 |
2020-01-28 |
Univ California |
compositions and methods to treat cancer
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
US11059819B2
(en)
|
2017-01-26 |
2021-07-13 |
Janssen Biotech, Inc. |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
AU2018240462C1
(en)
|
2017-03-23 |
2022-12-08 |
Graybug Vision, Inc. |
Drugs and compositions for the treatment of ocular disorders
|
CN111201040A
(en)
|
2017-05-10 |
2020-05-26 |
灰色视觉公司 |
Sustained release microparticles and suspensions thereof for medical therapy
|
WO2018218071A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
CA3063440A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
KR20200019228A
(en)
|
2017-06-21 |
2020-02-21 |
미토키닌, 인크. |
Compositions for the Treatment of Neurodegenerative and Mitochondrial Diseases and Methods of Using the Same
|
WO2019006371A1
(en)
|
2017-06-30 |
2019-01-03 |
City Of Hope |
Compositions and methods of modulating macrophage activity
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
Chimeric antigen receptors and bispecific antibodies for treatment of mantle cell lymphoma
|
MA50664A
(en)
|
2017-09-29 |
2020-08-05 |
Genentech Inc |
PEPTIDIC ANTIBIOTIC COMPLEXES AND THEIR METHODS OF USE
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
CA3078942A1
(en)
|
2017-10-10 |
2019-04-18 |
Syros Pharmaceuticals, Inc. |
Pyrrolotriazine compounds and methods of inhibiting tam kinases
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
UY37958A
(en)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
INTEGRATED STRESS ROAD MODULATORS
|
UY37957A
(en)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
INTEGRATED STRESS ROAD MODULATORS
|
US20200361881A1
(en)
|
2017-11-02 |
2020-11-19 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
EP3704091A1
(en)
|
2017-11-02 |
2020-09-09 |
Calico Life Sciences LLC |
Modulators of the integrated stress pathway
|
WO2019090074A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
UY37956A
(en)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
INTEGRATED STRESS ROAD MODULATORS
|
CA3080948A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
BR112020008825A2
(en)
|
2017-11-02 |
2020-10-20 |
Calico Life Sciences Llc |
modulators of the integrated stress pathway
|
CA3080971A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
BR112020009055A2
(en)
|
2017-11-06 |
2020-11-03 |
Rapt Therapeutics, Inc. |
chemokine receptor modulators for positive cancer treatment for epstein-Barr virus
|
KR20200096941A
(en)
|
2017-12-07 |
2020-08-14 |
앰플릭스 파마슈티컬스, 인크. |
Heterocycle-substituted pyridine derivatives antifungal agents
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
EP3740206B1
(en)
|
2018-01-16 |
2024-03-06 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2019143719A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
KR20200125932A
(en)
|
2018-01-26 |
2020-11-05 |
랩트 테라퓨틱스, 인크. |
Chemokine receptor modulators and uses thereof
|
CA3093802A1
(en)
|
2018-03-13 |
2019-09-19 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
CA3098562A1
(en)
|
2018-04-27 |
2019-10-31 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
AU2019262979B2
(en)
|
2018-05-01 |
2023-07-06 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mTOR inhibitors
|
US20190336609A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
|
EP3787618A4
(en)
|
2018-05-04 |
2022-05-04 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
|
EP3802544A1
(en)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
WO2019246513A1
(en)
|
2018-06-21 |
2019-12-26 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
JP2021530445A
(en)
|
2018-06-25 |
2021-11-11 |
アンプリックス ファーマシューティカルズ,インク. |
Pyridine derivatives substituted with heterocycles and amino groups
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
TWI771621B
(en)
|
2018-10-11 |
2022-07-21 |
美商嘉來克生命科學有限責任公司 |
Prodrug modulators of the integrated stress pathway
|
WO2020088659A1
(en)
|
2018-11-01 |
2020-05-07 |
Lynk Pharmaceuticals Co. Ltd. |
Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
|
KR20230074822A
(en)
|
2019-03-14 |
2023-05-31 |
칼리코 라이프 사이언시스 엘엘씨 |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
CA3138182A1
(en)
|
2019-04-30 |
2020-11-05 |
Calico Life Sciences Llc |
Substituted cycloalkyls as modulators of the integrated stress pathway
|
CN114126596A
(en)
|
2019-05-15 |
2022-03-01 |
贝克森生物医药公司 |
Ketamine formulations for subcutaneous injection
|
EP4031547A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof
|
EP4031245A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
MX2022003192A
(en)
|
2019-09-18 |
2022-04-11 |
Novartis Ag |
Nkg2d fusion proteins and uses thereof.
|
KR20220101099A
(en)
|
2019-11-13 |
2022-07-19 |
랩트 테라퓨틱스, 인크. |
Crystalline forms of C-C chemokine receptor type 4 antagonists and uses thereof
|
JP2023507774A
(en)
|
2019-12-18 |
2023-02-27 |
カリコ ライフ サイエンシーズ エルエルシー |
Protein tyrosine phosphatase inhibitors and methods of using them
|
AU2021276656A1
(en)
|
2020-05-19 |
2022-11-24 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
KR20230051486A
(en)
|
2020-08-18 |
2023-04-18 |
사이빈 아이알엘 리미티드 |
Therapeutic phenethylamine compositions and methods of use
|
US20220133735A1
(en)
|
2020-11-02 |
2022-05-05 |
Trethera Corporation |
Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
|
JP2023551145A
(en)
|
2020-11-18 |
2023-12-07 |
ベクソン バイオメディカル,インク. |
Complexing agent salt formulations of pharmaceutical compounds
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
EP4308564A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|
WO2022197763A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Inhibitors of plasma kallikrein
|
EP4308228A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors
|
EP4308227A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Imidazopyridinyl inhibitors of plasma kallikrein
|
JP2024516073A
(en)
|
2021-03-17 |
2024-04-12 |
武田薬品工業株式会社 |
Heteroaryl inhibitors of plasma kallikrein
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
WO2023156450A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
WO2023196432A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|